Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation

Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Gary Lee Chin Keong, Narayanaswamy Venketasubramanian, Nannette Rey, Gregorio Rogelio, Radhika Mehta

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation. At the Asia Pacific Advancing Patient care with EdoXaban 2023 meeting, experts shared insights on gastrointestinal bleeding with NOACs for stroke prevention in atrial fibrillation in Asian clinical practice, where NOACs have gained widespread acceptance due to their favourable profiles. Gastrointestinal bleeding risk varies amongst NOACs, emphasizing the importance of diligent patient assessment, dosage selection and vigilant monitoring. Edoxaban emerged as a viable option with a low gastrointestinal bleeding risk profile in Asian compared with non-Asian patients, supporting its continued clinical utilization for appropriate patients.

Article Details

Article Type

Meeting Report

DOI

10.7573/dic.2024-5-5

Publication Dates

Accepted: ; Published: .

Citation

Diaz AB, Chow J, Hoo FK, Keong GLC, Venketasubramanian N, Rey N, Rogelio G, Mehta R. Risk of gastrointestinal bleeding in Asian patients receiving oral anticoagulants for stroke prevention in atrial fibrillation. Drugs Context. 2024;13:2024-5-5. https://doi.org/10.7573/dic.2024-5-5

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.